Denali Therapeutics Inc. (DNLI): Price and Financial Metrics

Denali Therapeutics Inc. (DNLI): $70.01

-3.72 (-5.05%)

POWR Rating

Component Grades














  • Value is the dimension where DNLI ranks best; there it ranks ahead of 68.49% of US stocks.
  • DNLI's strongest trending metric is Quality; it's been moving up over the last 31 weeks.
  • DNLI's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

DNLI Stock Summary

  • DNLI's current price/earnings ratio is 154.12, which is higher than 94.75% of US stocks with positive earnings.
  • With a price/sales ratio of 26.23, Denali Therapeutics Inc has a higher such ratio than 91.74% of stocks in our set.
  • As for revenue growth, note that DNLI's revenue has grown 1,203.75% over the past 12 months; that beats the revenue growth of 99.12% of US companies in our set.
  • Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are CLGN, BPMC, CARA, GBT, and SGBX.
  • Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to

DNLI Price Target

For more insight on analysts targets of DNLI, see our DNLI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.89 Average Broker Recommendation 1.55 (Moderate Buy)

DNLI Stock Price Chart Interactive Chart >

Price chart for DNLI

DNLI Price/Volume Stats

Current price $70.01 52-week high $93.94
Prev. close $73.73 52-week low $22.36
Day low $70.01 Volume 1,531
Day high $70.01 Avg. volume 572,971
50-day MA $61.04 Dividend yield N/A
200-day MA $59.95 Market Cap 8.48B

Denali Therapeutics Inc. (DNLI) Company Bio

Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.

DNLI Latest News Stream

Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream

Loading social stream, please wait...

View Full DNLI Social Stream

Latest DNLI News From Around the Web

Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.

Former FDA Commissioner Hahn joins VC firm that helped launch Moderna

Chip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as a chief medical officer. Hahn will lead Flagship's Preemptive Medicine and Health Security initiative beginning on Wednesday. More than a...

Seeking Alpha | June 15, 2021

Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?

Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Yahoo | June 15, 2021

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative

Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.

Yahoo | June 14, 2021

Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis

Regarding the trend, note that the strongest trend exists on the 50 day timeframe. The post Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | June 8, 2021

Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 2, 2021

Read More 'DNLI' Stories Here

DNLI Price Returns

1-mo 18.86%
3-mo 20.29%
6-mo -20.51%
1-year 196.53%
3-year 290.25%
5-year N/A
YTD -16.42%
2020 380.83%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8781 seconds.